Tesamorelin (Egrifta): FDA-Approved GHRH Analog for Visceral Fat Research

Key Points

• Tesamorelin is the only FDA-approved growth hormone releasing hormone (GHRH) analog
• Brand name Egrifta® approved in 2010 for HIV-associated lipodystrophy
• Synthetic 44-amino acid peptide (GHRH 1-44 with trans-3-hexenoic acid modification)
• Primary mechanism: Stimulates pituitary GH release via GHRH receptor
• Clinical trials demonstrate significant visceral adipose tissue reduction
• Does not cause GH-like side effects (no direct IGF-1 elevation)

Table of Contents

1. Introduction
2. Molecular Structure
3. Mechanism of Action
4. FDA Approval & Clinical Use
5. Visceral Fat Reduction
6. Clinical Trial Data
7. Research Protocols
8. Safety Profile
9. Comparison to Other GHRH Analogs
10. Conclusion
11. References

Introduction

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), modified at the N-terminus with a trans-3-hexenoic acid group. This modification enhances stability while maintaining full biological activity at the GHRH receptor on pituitary somatotrophs.

Marketed as Egrifta®, Tesamorelin is the only GHRH analog to receive FDA approval, specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. This regulatory milestone distinguishes it from other research peptides in the GH secretagogue space.

Unlike exogenous GH administration, Tesamorelin works through the body's natural regulatory systems, stimulating endogenous GH production while maintaining normal feedback mechanisms. This approach produces physiological GH pulsatility rather than the continuous elevations seen with direct GH injection.

Molecular Structure

Chemical Properties

Structural Characteristics

GHRH Sequence: Tesamorelin retains the full bioactive GHRH(1-44) sequence with an N-terminal modification:

• Trans-3-hexenoic acid-Tyr(1)-Ala(2)-Asp(3)... through Leu(44)
• The modification protects against aminopeptidase degradation
• Full receptor binding affinity preserved
• Enhanced plasma stability vs native GHRH

Functional Regions:

• Residues 1-29: Required for receptor binding and activation
• Residues 30-44: Enhance potency and stability
• N-terminal modification: Extends half-life

Mechanism of Action

GHRH Receptor Activation

Tesamorelin binds the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs:

Signaling Cascade:

1. GHRH-R binding (Gs-coupled receptor)
2. Adenylate cyclase activation
3. cAMP production
4. Protein kinase A activation
5. GH gene transcription and secretion

Physiological GH Release:

• Maintains natural pulsatile pattern
• Preserves negative feedback mechanisms
• No direct IGF-1 elevation (secondary to GH)
• Does not suppress endogenous GHRH

Distinct from GHRPs

Visceral Fat Effects

Tesamorelin's fat-reducing mechanism involves:

1. GH-Mediated Lipolysis: Elevated GH activates hormone-sensitive lipase
2. Visceral Selectivity: Visceral adipose tissue highly responsive to GH
3. Metabolic Effects: Improved lipid profiles, reduced liver fat
4. IGF-1 Normalization: Secondary IGF-1 changes support metabolism

FDA Approval & Clinical Use

Regulatory Status

Lipodystrophy Context

HIV-associated lipodystrophy involves:

• Central Fat Accumulation: Visceral adipose tissue increase
• Peripheral Fat Loss: Limb and facial fat wasting
• Metabolic Dysfunction: Insulin resistance, dyslipidemia
• Cardiovascular Risk: Increased due to visceral fat

Tesamorelin addresses central fat accumulation without affecting peripheral fat or worsening metabolic parameters.

Prescribing Considerations

• Approved only for HIV lipodystrophy
• Requires diagnosis of excess abdominal fat
• Not approved for general obesity or bodybuilding
• Contraindicated with active malignancy (GH stimulation)

Visceral Fat Reduction

Clinical Evidence

Multiple Phase III trials demonstrated:

Characteristics of Fat Loss

Visceral-Specific:

• Targets intra-abdominal fat
• Less effect on subcutaneous fat
• No change in limb fat (important for lipodystrophy)

Measurement Methods:

• CT scan at L4-L5 level
• VAT area reduction quantified
• Trunk fat also reduced

Reversibility:

• Fat tends to return if treatment stopped
• Maintenance therapy considerations
• Not a permanent cure

Clinical Trial Data

Pivotal Trials

Study 1: 26-Week Phase 3 (Falutz et al., 2007)

• n = 412 HIV patients with lipodystrophy
• Tesamorelin 2mg vs placebo daily
• Primary endpoint: VAT change by CT
• Results: -15.4% vs +5% (significant)

Study 2: 52-Week Extension

• Continued responders showed maintained effect
• Some subjects showed further VAT reduction
• Safety profile consistent with 26-week data

Secondary Outcomes

Long-Term Data

• Studies up to 26 weeks published
• Visceral fat reduction maintained
• No evidence of tachyphylaxis
• Continued monitoring recommended

Research Protocols

Approved Clinical Dosing

Research Applications

Lipodystrophy Models:

• HIV-associated lipodystrophy
• Non-HIV lipodystrophy research
• Metabolic syndrome studies

Visceral Fat Studies:

• Mechanism of GH-mediated lipolysis
• Visceral adipose tissue biology
• Cardiovascular risk factor research

GHRH Pathway Research:

• Receptor characterization
• GH axis physiology
• Comparison to synthetic GHRPs

Administration

Reconstitution:

• Use provided sterile water
• Gently swirl (do not shake)
• Clear solution required
• Administer immediately after reconstitution

Injection Sites:

• Abdomen (recommended)
• Rotate injection sites
• Subcutaneous only

Safety Profile

Clinical Trial Adverse Events

GH-Related Effects

Unlike exogenous GH, Tesamorelin produces:

• Less fluid retention: Physiological vs supraphysiological
• Lower carpal tunnel risk: Natural pulsatility
• Maintained feedback: Self-limiting GH elevation
• Normal glucose: No significant diabetogenic effect

Contraindications

Monitoring

• IGF-1 levels (should not exceed normal)
• Glucose (especially if diabetic)
• Edema assessment
• Injection site monitoring

Comparison to Other GHRH Analogs

GHRH Compound Overview

Tesamorelin Advantages

1. FDA Approval: Only approved GHRH analog
2. Full Sequence: 44 amino acids (more complete than 29-AA versions)
3. Clinical Data: Extensive Phase 3 trial data
4. Stability: N-terminal modification extends activity

Sermorelin Comparison

Conclusion

Tesamorelin represents a unique position in the peptide landscape as the only FDA-approved GHRH analog. Its documented efficacy in reducing visceral adipose tissue in HIV-associated lipodystrophy established it as a legitimate pharmaceutical with clinical trial validation.

The mechanism—stimulating endogenous GH release through the GHRH receptor—produces physiological GH pulsatility rather than the continuous elevation seen with exogenous GH. This approach maintains natural feedback mechanisms while effectively targeting visceral fat accumulation.

For research applications, Tesamorelin offers a well-characterized compound with extensive clinical data, making it valuable for studies on GH axis physiology, visceral fat metabolism, and lipodystrophy intervention strategies.

References

1. Falutz J, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med.

2. Stanley TL, et al. (2014). Effects of tesamorelin on inflammatory markers in HIV patients. J Clin Endocrinol Metab.

3. Dhillon S. (2011). Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs.

4. FDA Prescribing Information. Egrifta (tesamorelin for injection).

5. Theratechnologies Inc. Clinical study reports for tesamorelin.

6. Koutkia P, et al. (2004). Growth hormone-releasing hormone in HIV-infected men with lipodystrophy. JAMA.